The efficacy and safety of exogenous melatonin for primary sleep disorders a meta-analysis

Buscemi, Nina; Vandermeer, Ben; Hooton, Nicola; Pandya, Rena; Tjosvold, Lisa; Hartling, Lisa; Baker, Glen B.; Klassen, Terry P.; Vohra, Sunita

doi:10.1111/j.1525-1497.2005.0243.x

Cited by 357 publications

(200 citation statements)

References 40 publications

(60 reference statements)

Supporting

Mentioning

184

Contrasting

Unclassified

Order By: Relevance

“…A meta‐analysis of controlled human intervention studies in normal sleepers and subjects with primary insomnia indicated a statistically significant reduction of sleep onset latency following immediate release (IR) melatonin consumption (Buscemi et al, 2005; Zisapel, 2012). Melatonin did not improve any other aspects of sleep quantity.…”

Section: Melatonin In the Treatment Of Circadian Rhythm And Sleep Dismentioning

confidence: 99%

New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation

Zisapel

2018

British J Pharmacology

498

310

View full text Add to dashboard Cite

In mammals, a central circadian clock, located in the suprachiasmatic nuclei (SCN) of the hypothalamus, tunes the innate circadian physiological rhythms to the ambient 24 h light–dark cycle to invigorate and optimize the internal temporal order. The SCN‐activated, light‐inhibited production of melatonin conveys the message of darkness to the clock and induces night‐state physiological functions, for example, sleep/wake blood pressure and metabolism. Clinically meaningful effects of melatonin treatment have been demonstrated in placebo‐controlled trials in humans, particularly in disorders associated with diminished or misaligned melatonin rhythms, for example, circadian rhythm‐related sleep disorders, jet lag and shift work, insomnia in children with neurodevelopmental disorders, poor (non‐restorative) sleep quality, non‐dipping nocturnal blood pressure (nocturnal hypertension) and Alzheimer's disease (AD). The diminished production of melatonin at the very early stages of AD, the role of melatonin in the restorative value of sleep (perceived sleep quality) and its sleep‐anticipating effects resulting in attenuated activation of certain brain networks are gaining a new perspective as the role of poor sleep quality in the build‐up of β amyloid, particularly in the precuneus, is unravelled. As a result of the recently discovered relationship between circadian clock, sleep and neurodegeneration, new prospects of using melatonin for early intervention, to promote healthy physical and mental ageing, are of prime interest in view of the emerging link to the aetiology of Alzheimer's disease.Linked ArticlesThis article is part of a themed section on Recent Developments in Research of Melatonin and its Potential Therapeutic Applications. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.16/issuetoc

show abstract

Section: Melatonin In the Treatment Of Circadian Rhythm And Sleep Dismentioning

confidence: 99%

New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation

Zisapel

2018

British J Pharmacology

498

310

View full text Add to dashboard Cite

show abstract

“…Meta-analysis studies have shown that when using melatonin to reset the circadian rhythm, no adverse effects are induced, neither in short-term nor long-term use [22,23] . Rossignol and Frye found that hormone use did not lead to adverse events in 7 of 12 studies in which children with ASD were treated with melatonin [24] .…”

Section: Scheme Of the Biosynthesis Of Melatonin In Vivomentioning

confidence: 99%

Comparative Study between the use of Melatonin and A Solution with Melatonin, Tryptophan, and Vitamin B6 as an Inducer of Spontaneous Sleep in Children During an Auditory Response Test: An Alternative to Commonly Used Sedative Drugs

Volpe¹,

Lucia²,

Pirozzi³

et al. 2017

Int Adv Otol

View full text Add to dashboard Cite

MATERIALS and METHODS:In total, 748 children aged between 12 and 48 months were included in the study and divided into three groups: A: placebo (n=235), B: melatonin (n=246), and C: melatonin, tryptophan, and vitamin B6 (n=267). RESULTS:In groups B and C, in addition to physiological awakening, we observed a significant reduction in the number of repeated analyses as well as drug regimen usage. CONCLUSION:This study confirms the strategic role of melatonin as an inducer of spontaneous sleep. However, above all, it suggests that the administration of a solution containing melatonin, tryptophan, and vitamin B6 significantly reduces the number of repeated ABR examinations as well as the percentage of repeated analysis performed using sedative drugs compared to both the control group and the melatonin-only group.

show abstract

“…A previous meta-analysis demonstrated that melatonin was beneficial in treating most primary sleep disorders over the shortterm (4 weeks or less) [17]. However, since this meta-analysis, 7 trials have been published with an additional 1258 subjects.…”

Section: Introductionmentioning

confidence: 99%

Meta-Analysis: Melatonin for the Treatment of Primary Sleep Disorders

Ferracioli-Oda¹,

Qawasmi²,

Bloch³

2014

FOC

View full text Add to dashboard Cite

Study Objectives: To investigate the efficacy of melatonin compared to placebo in improving sleep parameters in patients with primary sleep disorders.Design: PubMed was searched for randomized, placebo-controlled trials examining the effects of melatonin for the treatment of primary sleep disorders. Primary outcomes examined were improvement in sleep latency, sleep quality and total sleep time. Meta-regression was performed to examine the influence of dose and duration of melatonin on reported efficacy.Participants: Adults and children diagnosed with primary sleep disorders.Interventions: Melatonin compared to placebo. Conclusion:This meta-analysis demonstrates that melatonin decreases sleep onset latency, increases total sleep time and improves overall sleep quality. The effects of melatonin on sleep are modest but do not appear to dissipate with continued melatonin use. Although the absolute benefit of melatonin compared to placebo is smaller than other pharmacological treatments for insomnia, melatonin may have a role in the treatment of insomnia given its relatively benign side-effect profile compared to these agents.

show abstract

The efficacy and safety of exogenous melatonin for primary sleep disorders a meta-analysis

Cited by 357 publications

References 40 publications

New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation

New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation

Comparative Study between the use of Melatonin and A Solution with Melatonin, Tryptophan, and Vitamin B6 as an Inducer of Spontaneous Sleep in Children During an Auditory Response Test: An Alternative to Commonly Used Sedative Drugs

Meta-Analysis: Melatonin for the Treatment of Primary Sleep Disorders

Contact Info

Product

Resources

About